Dr. Andrin Oswald, MD, is a distinguished pharmaceutical executive with extensive experience in global health initiatives and vaccine development. He earned his Doctor of Medicine from the University of Geneva in 1999. Dr. Oswald has held several key leadership positions throughout his career. He served as the Chief Executive Officer of Speedel Holding AG, which was later acquired by Novartis AG. At Novartis, he was the CEO and Division Head of Novartis Vaccines and Diagnostics from 2008 until its acquisition by GSK in 2015, and was a member of the executive committee. Following his tenure at Novartis, Dr. Oswald joined the Bill & Melinda Gates Foundation as the Director of Life Sciences Partnerships, overseeing the foundation's engagements with corporations. In 2020, he was appointed as the Chief Executive Officer of Centogene N.V., a company focused on rare diseases. In addition to his corporate roles, Dr. Oswald contributed to global health efforts as the Delegate for COVID-19 Vaccines and Immunotherapies for the Federal Government of Switzerland, advising on response and procurement strategies during the pandemic. Dr. Oswald's extensive experience in the pharmaceutical industry equip our team with world-class experience in pharmaceuticals and global health.

Roman Fleck, PhD, MBA, is a seasoned biotechnology executive with over two decades of experience in pharmaceutical research, venture investment, and company leadership. He currently serves as the Chairman of the Board at Iktos, a company specializing in generative AI for drug discovery, as well as the Executive Chairman of HDAX Therapeutics, which focuses on neurological and cardiac diseases.. And until recently, he served as the Chairman of Omniose, a bacterial vaccine discovery company, Previously, Dr. Fleck was theCo-Founder and Chief Executive Officer of Janpix (aquired by Centessa Pharmaceuticals), an oncology-focused biotech company. He has also held roles as a Venture Advisor / Partner at Medicxi Ventures, where he invested in and represented companies on the boards of GlycoVaxyn (acquired by GSK), Versartis (NASDQ: VSAS), and Novocure (NASDQ: NVCR). He was also involved in Funxional Therapeutics (acquired by Boehringer Ingelheim) and Micromet (acquired by Amgen). Earlier in his career, Dr. Fleck led drug development projects in oncology, inflammation, and cardiovascular disease at Boehringer Ingelheim, advancing several compounds from pre-clinical to clinical stages. He earned his PhD in Organic Chemistry from the Massachusetts Institute of Technology (MIT) and an MBA from New York University's Stern School of Business.

Dr. Ana Montalban-Arques is a scientist-entrepreneur dedicated to transforming cancer treatment through innovative immunotherapy solutions. With a strong background in tumor immunology, microbiome research, and translational medicine, she leads the development of cutting-edge therapies aimed at harnessing the body’s own defenses to fight cancer more effectively. She earned her PhD in Human Medicine from the Medical University of Graz (Austria) and holds a Master’s in Molecular Biology and Biotechnology as well as a Bachelor’s in Biology from the University of Murcia (Spain). Her scientific expertise spans oncology, immunotherapy, and host-microbiome interactions, laying the foundation for her pioneering work in biotech innovation. Prior to founding Adularia (formerly known as Recolony), Dr. Montalban-Arques held leadership and research positions at the University of Zurich, where she spearheaded projects in the Department of Gastroenterology and Hepatology, focusing on the interplay between cancer, microbiome, and the immune system. She also gained experience as a Postdoctoral Research Fellow at Hospital Universitario de La Princesa in Madrid, Spain. As the Co-Founder and CEO of Adularia, she drives the company’s vision to develop first-in-class tumor-targeted immunotherapies. Under her leadership, Adularia is advancing a novel small molecule therapy with the goal of enhancing treatment efficacy while minimizing side effects.